RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Down 63.1% in May

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 382,900 shares, a decrease of 63.1% from the May 15th total of 1,037,400 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

RemeGen Stock Performance

Shares of REGMF stock remained flat at $5.06 during mid-day trading on Friday. The stock has a 50-day moving average price of $3.99 and a two-hundred day moving average price of $2.36. RemeGen has a 1-year low of $1.50 and a 1-year high of $5.10.

RemeGen Company Profile

RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.